switch semaglutide to tirzepatide TrimRX Switching from Semaglutide to Tirzepatide:

Safety First: Talk to Your Doctor Before beginning any new exercise program, particularly when managing a health condition or taking medications like GLP-1 agonists, it is essential to consult with a healthcare provider

The FDA states that compounded drugs are "not reviewed by FDA prior to marketing and are not FDA-approved." What this means for consumers: When accessing compounded semaglutide or tirzepatide through telehealth platforms, you are receiving a medication that contains the same active ingredient as FDA-approved products but is prepared differently and has not undergone FDA approval as a finished product

While structurally similar, it is inaccurate (and perhaps unlawful) to refer to a compounded drug by the trade name assigned by the pharmaceutical company owning the patent

If you are using a program through TrimRx that utilizes Compounded Semaglutide or Compounded Tirzepatide, these are almost exclusively once-weekly injections

What PlushCare is PlushCare (Accolade (PlushCare)) operates as subscription telehealth

The MHRA has issued warnings about the risks of obtaining unlicensed injectable peptides including GLP-1 receptor agonists from unregulated online sources, citing concerns about uncertain purity and potency, absence of validated stability data, risk of microbial contamination in preparations not manufactured under Good Manufacturing Practice (GMP) conditions, and the potential for mislabelling or adulteration